Quick Answer
PURE BIOSCIENCE, INC. reported Total Revenue of $2.20 million for fiscal year 2025.
PURE BIOSCIENCE, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.20M +12.2% |
$1.96M +4.6% |
$1.88M +1.3% |
$1.85M -52.8% |
$3.93M -43.2% |
$6.92M +262.3% |
| Revenue (ASC 606) | $2.20M +12.2% |
$1.96M +4.6% |
$1.88M +1.3% |
$1.85M -52.8% |
$3.93M -43.2% |
$6.92M +262.3% |
| Net Income | -$2.40M +28.4% |
-$3.35M +15.4% |
-$3.96M -13.5% |
-$3.49M -50.5% |
-$2.32M -58075.0% |
$4.0K +100.1% |
| Diluted EPS | -$0.02 +33.3% |
-$0.03 +25.0% |
-$0.04 +0.0% |
-$0.04 -33.3% |
-$0.03 | $0.00 +100.0% |
| Total Assets | $1.06M +29.3% |
$818.0K -55.2% |
$1.82M -59.3% |
$4.48M +4.2% |
$4.30M -31.9% |
$6.32M +227.3% |
| Cash and Equivalents | $334.0K -4.3% |
$349.0K -68.1% |
$1.09M -67.7% |
$3.39M +41.9% |
$2.39M -37.7% |
$3.84M +864.6% |
| Stockholders Equity | -$5.12M -78.6% |
-$2.86M -1152.9% |
$272.0K -93.0% |
$3.91M +17.3% |
$3.33M -30.7% |
$4.81M +304.3% |
| R&D Expense | $316.0K +4.6% |
$302.0K +1.7% |
$297.0K -6.9% |
$319.0K -5.9% |
$339.0K +5.3% |
$322.0K -9.0% |
| Operating Income | -$2.27M +28.8% |
-$3.19M +19.1% |
-$3.94M -5.9% |
-$3.72M -61.1% |
-$2.31M -57875.0% |
$4.0K +100.1% |
| Gross Profit | $1.30M +13.1% |
$1.15M +18.6% |
$971.0K -2.9% |
$1.00M -51.8% |
$2.08M -48.4% |
$4.02M +240.5% |
| Shares Outstanding | 111.89M +0.0% |
111.86M +0.0% |
111.86M +0.4% |
111.36M +27.7% |
87.22M +0.2% |
87.07M +13.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | January 31, 2026 | $444.0K | +13.6% | -37.3% |
| Revenue (ASC 606) | January 31, 2026 | $444.0K | +13.6% | -37.3% |
| Net Income | January 31, 2026 | -$785.0K | +1.6% | -69.2% |
| Diluted EPS | January 31, 2026 | -$0.01 | +0.0% | — |
| Total Assets | January 31, 2026 | $788.0K | +37.3% | -33.6% |
| Cash and Equivalents | January 31, 2026 | $198.0K | -2.0% | -54.4% |
| Stockholders Equity | January 31, 2026 | -$6.27M | -47.0% | -13.1% |
| R&D Expense | January 31, 2026 | $74.0K | -8.6% | -14.0% |
| Operating Income | January 31, 2026 | -$683.0K | +5.8% | -80.2% |
| Gross Profit | January 31, 2026 | $238.0K | +4.8% | -47.1% |
| Shares Outstanding | January 31, 2026 | 111.89M | +0.0% | +0.0% |
- PURE BIOSCIENCE, INC. reported Total Revenue of $2.20 million for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed an increase of +12.2% in Total Revenue compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported Revenue (ASC 606) of $2.20 million for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed an increase of +12.2% in Revenue (ASC 606) compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported Net Income of -$2.40 million for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed an increase of +28.4% in Net Income compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed an increase of +33.3% in Diluted EPS compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported Total Assets of $1.06 million for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed an increase of +29.3% in Total Assets compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported Cash and Equivalents of $334.0 thousand for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed a decrease of -4.3% in Cash and Equivalents compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported Stockholders Equity of -$5.12 million for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed a decrease of -78.6% in Stockholders Equity compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported R&D Expense of $316.0 thousand for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed an increase of +4.6% in R&D Expense compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported Operating Income of -$2.27 million for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed an increase of +28.8% in Operating Income compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported Gross Profit of $1.30 million for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed an increase of +13.1% in Gross Profit compared to the prior fiscal year.
- PURE BIOSCIENCE, INC. reported Shares Outstanding of 111.89 million shares for fiscal year 2025.
- PURE BIOSCIENCE, INC. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: